Cloud-Based Platform Enlists Quest to Provide COVID-19 Molecular Test Results to Travelers
As proof of COVID-19 vaccination and/or negative molecular test results morphs into a passport for air travel and attending live events, labs with the capacity to generate rapid and reliable tests and results on an expansive geographic scale will be in growing demand. Quest Diagnostics has been quick to recognize and take advantage of this […]
As proof of COVID-19 vaccination and/or negative molecular test results morphs into a passport for air travel and attending live events, labs with the capacity to generate rapid and reliable tests and results on an expansive geographic scale will be in growing demand. Quest Diagnostics has been quick to recognize and take advantage of this opportunity by enlisting as a test provider for TrustAssure.
The TrustAssure Platform
Created by CLX Health, a developer of cloud-based solutions owned by SiriusIQ, the TrustAssure Global Testing Platform collaborates with physicians, clinics, hospitals and other providers in 5,000 U.S. and 15,000 global locations to provide test results to travelers and meeting attendees needing COVID-19 clearance to go through with their plans. Quest will become the first national provider of molecular COVID-19 testing to participate in TrustAssure.
The newly announced Quest/CLX Health collaboration will enable individuals to use the TrustAssure platform to schedule test appointments at Quest patient centers and more than 750 retail pharmacy partner locations across the country knowing that they’ll get their results within 48 hours. This way, they can secure the “passport” they need to fly or attend the event in advance.
It’s an ideal strategic collaboration: CLX Health secures Quest’s massive molecular testing capabilities to bolster its solution; in turn, Quest gets to leverage the TrustAssure platform, which integrates the IBM Digital Health Pass, to reach the air travel and live events markets.
“COVID-19 testing is a powerful tool for providing insights that can foster safer environments,” noted Cathy Doherty, Quest senior VP and group executive, clinical franchise solutions and marketing. “As COVID-19 restrictions are lifted around the country and world, our collaboration with TrustAssure will allow us to facilitate high-quality testing for individuals looking to get back to recreation and travel.”
This is hardly Quest’s first venture into consumer empowerment over lab test results. The company was among the first diagnostic information services provider to offer free online access to test results. The lab giant also offers the MyQuest mobile app and patient portal enabling consumers to access and track their test results, as well as the QuestDirect service providing tests for various health conditions, illnesses and infections.
Here’s a summary of other key strategic diagnostic deals announced in July 2021:
STRATEGIC ALLIANCES, PARTNERSHIPS & COLLABORATIONS
|Partner 1||Partner(s) 2+||Deal Summary|
|Oncimmune Holdings||Dana-Farber Cancer Institute|
|Ibex Medical Analytics||Unilabs|
|Quest Diagnostics||CLX Health|
|Mission Bio||Sequanta Technologies|
|GE Healthcare||SOPHiA GENETICS|
|Thermo Fisher Scientific||Ortho Clinical Diagnostics|
|Nonacus||University of Birmingham (UK)|
DISTRIBUTION, SALES & MARKETING AGREEMENTS
|Product Owner||Distributor||Deal Summary|
|PixCell Medical||Gamidor Diagnostics|
|Fosun Pharma||Todos Medical|
|Microbix Biosystems||Thomas Scientific|
|Shoreline Biome||AH Diagnostics|
|IBM Research||NanoDx||NanoDx licenses metal-oxide semi-conductive compatible nanoscale sensors to expand rapid testing for COVID-19, traumatic brain injury, sepsis and stroke|
|ERS Genomics||Japan SLC||Japanese biotech company gets nonexclusive access to ERS’ CRISPR-Cas9 patents to expand its animal model offerings|
|ERS Genomics||Nippon Gene||Japanese biotech company gets nonexclusive access to ERS’ CRISPR-Cas9 patents to develop, manufacture and sell research reagents|
SUPPLY, SERVICE, TESTING & MANUFACTURING AGREEMENTS
|Becton Dickinson||USA Track & Field||Becton Dickinson to provide rapid COVID-19 testing for USATF athletes with BD Veritor Plus system during Olympics qualifying events and trials|
|Contractor||Govt. Agency||Contract Summary|
|LightDeck Diagnostics||US Departments of Defense and Health and Human Services||$35.1 million contract to increase manufacturing capacity for LightDeck’s upcoming COVID-19 Ultra-Rapid Antigen and Total Antibody tests|
Subscribe to view Essential
Start a Free Trial for immediate access to this article